

Importance of accurate *EPCAM* deletion characterization to prevent misdiagnosis of Lynch syndrome

Horton C, MS¹; Mar-Heyming R, PhD¹; Hernandez F, PhD¹; Marsh APL, PhD¹; Harrison S, PhD¹; Grzybowski J, MS¹; Richardson ME, PhD¹; Kosteci D, MS¹; Lau C, PhD¹; Chao E, MD, PhD^{1,2}; Hampel H, MS³


1) Ambry Genetics 2) University of California, Irvine, School of Medicine 3) City of Hope

chorton@ambrygen.com

BACKGROUND

Prior to the introduction of NGS, *EPCAM* deletion screening was typically performed by one MLPA kit throughout the country. The only MLPA kit available does not have probe coverage 5' of exon 3, making it difficult to determine if a deletion spans the entire gene. Phenotypes of individuals with isolated whole *EPCAM* deletions are not well described and may have different clinical implications than individuals with partial deletions.

FIGURE 1. *EPCAM* and *MSH2* disease mechanism



METHODS

FIGURE 2. Cohort Selection




FIGURE 3. Sample MLPA Result





FIGURE 4. Isolated *EPCAM* Deletion Size



21% of individuals with isolated *EPCAM* deletions may have a full deletion. Re-evaluation in individuals not meeting criteria should be considered.

- Unknown Deletion Size
- Known Full Deletion
- Known Partial Deletion

Take Home Points

Isolated whole-gene *EPCAM* deletions do not appear to cause Lynch syndrome.

Some patients with *EPCAM*-associated Lynch syndrome may be misdiagnosed and eligible for re-evaluation.

